Holen Sie sich die Stockscreener-App
27.74
6.41%
-1.90
Handel nachbörslich:
27.74
Schlusskurs vom Vortag:
$29.64
Offen:
$29.5
24-Stunden-Volumen:
1.31M
Relative Volume:
1.88
Marktkapitalisierung:
$1.95B
Einnahmen:
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-8.7334
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
-10.80%
1M Leistung:
-26.13%
6M Leistung:
-3.61%
1J Leistung:
+26.90%
1-Tages-Spanne:
$27.68
$29.54
1-Wochen-Bereich:
$27.68
$31.93
52-Wochen-Spanne:
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
27.74 | 1.95B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-15 | Eingeleitet | Wells Fargo | Overweight |
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Singapore
Pharvaris N.V. (PHVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet - GlobeNewswire Inc.
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance UK
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy - GlobeNewswire Inc.
Pharvaris (PHVS) Shares Edge Higher, Holding Firmly Above Key SupportSMA Signal - siam.in
Form 4 Pharvaris N.V. For: 26 September By Investing.com - Investing.com Nigeria
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Canada
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com UK
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan
Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan
Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris (NASDAQ: PHVS) officer to sell 100,000 shares under Rule 144 - Stock Titan
Shareholder at Pharvaris (NASDAQ: PHVS) plans multi-million-dollar stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) lines up $10.5M sale of founder stock - Stock Titan
Pharvaris (NASDAQ: PHVS) director plans nearly $2M stock sale in 2026 - Stock Titan
Founder shares in Pharvaris (NASDAQ: PHVS) set for $765K planned sale - Stock Titan
Pharvaris (NASDAQ: PHVS) director lines up new stock sale after recent trades - Stock Titan
Pharvaris N.V. (PHVS) exec sells 46,400 shares in cashless trade - Stock Titan
Souverijns Wim Executes Option Exercises and Sells 26,090 Pharvaris Shares - Kalkine Media
Officer at Pharvaris (NASDAQ: PHVS) plans potential $1.77M stock sale - Stock Titan
Director in Pharvaris (PHVS) lines up new sale after $300K stock trade - Stock Titan
Pharvaris (NASDAQ: PHVS) CEO sells 2,291 shares in 10b5-1 plan trade - Stock Titan
Pharvaris (NASDAQ: PHVS) exec files to sell shares from vested stock and options - Stock Titan
2,291 Pharvaris (Nasdaq: PHVS) shares set for resale - Stock Titan
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com South Africa
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com UK
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pharvaris Nv-Aktie (PHVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Monges Viviane | Director |
Sep 23 '26 |
Sale |
33.05 |
11,969 |
395,524 |
5,500 |
| VIVIANE ROSINE FRANCOISE BECK | Director |
Sep 23 '26 |
Proposed Sale |
33.05 |
11,969 |
395,524 |
0 |
| Schikan Johannes Gerardus Chri | Director |
Sep 22 '26 |
Option Exercise |
20.00 |
800 |
16,000 |
115,967 |
| JOHANNES GER. CHRIS. PE SCHIKA | Director |
Sep 22 '26 |
Proposed Sale |
36.19 |
800 |
28,952 |
0 |
| Lu Peng | President |
Sep 22 '26 |
Option Exercise |
2.59 |
45,308 |
117,348 |
110,261 |
| Schikan Johannes Gerardus Chri | Director |
Sep 22 '26 |
Sale |
36.19 |
800 |
28,952 |
115,167 |
| DAVID NASSIF | Officer |
Sep 21 '26 |
Proposed Sale |
36.47 |
6,000 |
218,801 |
0 |
| Nassif David W. | CFO / CLO |
Sep 21 '26 |
Sale |
36.47 |
6,000 |
218,801 |
114,300 |
| ROBERT GLASSMAN | Director |
Sep 17 '26 |
Proposed Sale |
38.56 |
14,493 |
558,812 |
0 |
| GRAYMATTERS CONSULTING | Officer |
Sep 17 '26 |
Proposed Sale |
38.27 |
20,000 |
765,466 |
0 |
5.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):